Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 1,568 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control regimen Clear all

Conditions: Epidermolysis Bullosa, Junctional, Epidermolysis Bullosa Dystrophica
Interventions: Apligraf, Standard dressing regimen; Device · Other
Lead sponsor: Organogenesis; Industry
Eligibility: 2 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 5
States / cities: Stanford, California • Miami, Florida • New York, New York + 2 more

Conditions: Adenotonsillectomy, Analgesia, Surgery
Interventions: Dexamethasone, Ibuprofen, Acetaminophen, Placebo; Drug
Lead sponsor: David Chi, MD; Other
Eligibility: 3 Years to 17 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Sewickley, Pennsylvania

Conditions: Asthma (Diagnosis)
Interventions: Sensor-Enabled mHealth Intervention for Adolescents with Suboptimal Asthma Control, mHealth standard of care control condition; Behavioral
Lead sponsor: University of Kansas; Other
Eligibility: 13 Years to 17 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Jacksonville, Florida • Lawrence, Kansas

Conditions: Bone Mineral Density
Interventions: 91-day Levonorgestrel Oral Contraceptive, 28-day Levonorgestrel Oral Contraceptive; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 12 Years to 18 Years · Female only
Enrollment: 1,361 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 46
States / cities: Phoenix, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 39 more

Conditions: Stroke
Interventions: Aggrenox, Clopidogrel placebo, Micardis, Aggrenox placebo, Clopidogrel, Micardis placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 50 Years and older
Enrollment: 20,332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 204
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 160 more

Conditions: Pain
Interventions: EXPAREL, Ketorolac, laparoscopic abdominal hernia repair, an open surgery for abdominal hernia repair; Drug · Procedure
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Prehypertension, Hypertension
Interventions: Sleep Enhancement, Health Education; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Acute Respiratory Failure, Covid19
Interventions: Life2000® Ventilator; Device
Lead sponsor: Hill-Rom; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Bloomington, Minnesota

Conditions: Type 2 Diabetes Mellitus
Interventions: Lixisenatide (AVE0010), Placebo, Insulin glargine, Pen auto-injector, Metformin, Thiazolidinedione (TZD); Drug · Device
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 23
States / cities: Mesa, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 19 more

Conditions: Lung Neoplasm, Carcinoma Non-small Cell Lung Cancer Stage IIIA, Carcinoma Non-small Cell Lung Cancer Stage IIIB, Carcinoma Non-small Cell Lung Cancer Stage IV
Interventions: Lucanix™, Placebo Comparator; Biological · Other
Lead sponsor: NovaRx Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 532 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 53
States / cities: Mobile, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 46 more

Conditions: PSP - Progressive Supranuclear Palsy
Interventions: AADvac1, Matching Placebo; Biological
Lead sponsor: Adam Boxer; Other
Eligibility: 41 Years to 86 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Travelers' Diarrhea, Functional Bowel Disorders, Reactive Arthritis
Interventions: Rifaximin, Placebo; Drug
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years and older
Enrollment: 449 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 5
States / cities: San Diego, California • Honolulu, Hawaii • Marine Corps Base Camp Lejeune, North Carolina + 2 more

Conditions: Arthropathy of Knee, Osteo Arthritis Knee, Osteonecrosis, Meditation, Knee Osteoarthritis, Knee Disease, Knee Injuries, Opioid Use, Opioid Dependence, Opioid Use Disorder
Interventions: Mindful meditation; Behavioral
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Macular Degeneration, Age-related, Geographic Atrophy
Interventions: BI 771716, Pegcetacoplan, Sham comparator to BI 771716; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 50 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 46
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 42 more

Conditions: HIV
Interventions: atazanavir/raltegravir, atazanavir/tenofovir/emtricitabine; Drug
Lead sponsor: Community Research Initiative of New England; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 9
States / cities: Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 6 more

Conditions: Clostridium Difficile Associated Disease
Interventions: C. difficile vaccine, C. difficile vaccine +adjuvant; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Pembroke Pines, Florida • South Miami, Florida • Overland Park, Kansas + 1 more

Conditions: Pain, Postoperative, Cardiac Surgery
Interventions: PECS2 block, Ropivacaine 0.5% Injectable Solution, Lidocaine Epinephrine, Dexmedetomidine 0.004 MG/ML; Procedure · Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Mineola, New York

Conditions: HIV Infections
Interventions: Enfuvirtide; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 16 Years and older
Enrollment: 525 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 34
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 27 more

Conditions: Cytomegalovirus (CMV) Infections
Interventions: V160, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years to 35 Years · Female only
Enrollment: 2,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 54
States / cities: Birmingham, Alabama • Chandler, Arizona • Rialto, California + 41 more

Conditions: Radiation Dermatitis
Interventions: Bacterial decolonization, Mometasone furoate 0.1% cream, Bacterial decolonization and Mometasone furoate 0.1% cream; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Arrythmia, Cardiomyopathies
Interventions: Intra-Op Prophylactic VT ablation, Conventional Management; Procedure · Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 19
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 15 more

Conditions: Community Acquired Pneumonia
Interventions: Zabofloxacin, Levofloxacin 500mg, Zabofloxacin 400mg; Drug
Lead sponsor: IASO Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 13
States / cities: Huntsville, Alabama • Toney, Alabama • Fort Myers, Florida + 10 more

Conditions: Chronic Spontaneous Urticaria (CSU), Chronic Idiopathic Urticaria
Interventions: THB335 Lower Dose, THB335 Higher Dose, Placebo; Drug
Lead sponsor: Calixis Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 15
States / cities: Pasadena, California • Ventura, California • Walnut Creek, California + 12 more

Conditions: Healthy
Interventions: Dasatinib, Quercetin, Fisetin; Drug
Lead sponsor: Sundeep Khosla, M.D.; Other
Eligibility: 60 Years and older · Female only
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB)

Post-operative Course of Dexamethasone to Reduce Tonsillectomy Morbidity

Optimizing a Sensor-Enabled mHealth Intervention for Adolescents With Suboptimal Asthma Control

A Multicenter Study to Evaluate the Effects of a 91-day Oral Contraceptive on Bone Mineral Density in Adolescent Females

PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes

Liposomal Bupivacaine (Exparel) for Postoperative Pain Control for Open and Laparoscopic Abdominal Hernia Repair

HELP-HY: Health Education and sLeep Program in HYpertension

Proportional Open Ventilation (POV) Device and Its Efficacy in Managing Acute Respiratory Failure in COVID-19 Patients

24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine

Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy

The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1

Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea - Prevent TD

Meditation and Opioid Consumption in Total Joint Replacement Patients Undergo Primary Total Hip and Knee Replacement

A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.

Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years

Pectoral Nerves Block to Relieve Post-sternotomy Pain After Cardiac Surgery

T-20 With Anti-HIV Combination Therapy for Patients With Prior Anti-HIV Drug Treatment and/or Drug Resistance to Each of the Three Classes of Approved Anti-HIV Drugs

V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)

Topical Steroids & Bacterial Decolonization for Radiation Dermatitis

The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients

Safety and Efficacy Study of Oral Zabofloxacin in Community Acquired Pneumonia

A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU)

Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans